Table 2.
PD1/PDL1 expression and CD8+T cells/CD68+M density in MSI and MSS GC
| MSI (%) | MSS (%) | Sum | P | |
|---|---|---|---|---|
| PD1 | 0.109 | |||
| Negative | 19(41) | 87(55) | 106 | |
| Positive | 27(59) | 72(45) | 99 | |
| Sum | 46(100) | 159(100) | 205 | |
| PDL1 [T] | 0.090 | |||
| Negative | 30(65) | 121(78) | 151 | |
| Positive | 16(35) | 35(22) | 51 | |
| Sum | 46(100) | 156(100) | 202 | |
| PDL1 | 0.044 | |||
| Negative | 20(43) | 94(60) | 114 | |
| Positive | 26(57) | 62(40) | 88 | |
| Sum | 46(100) | 156(100) | 202 | |
| CD8 | 0.537 | |||
| Low | 21(47) | 83(52) | 104 | |
| High | 24(53) | 77(48) | 101 | |
| Sum | 45(100) | 160(100) | 205 | |
| CD68 | <0.001 | |||
| Low | 7(16) | 95(60) | 102 | |
| High | 37(84) | 63(40) | 100 | |
| Sum | 44(100) | 158(100) | 202 |
GC: gastric cancer; MSI: microsatellite unstable; MSS: microsatellite stable; CD68+ M: CD68+ macrophage; PD1: programmed cell death protein 1; PDL1, programmed death ligand 1; In all 215 cases of gastric cancer, 205 cases immunohistochemical sections were evaluable for PD1, 202 cases for PDL1 [T]/PDL1, 205 cases for CD8, and 202 cases for CD68.